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1 Drug description 
Generic/Brand name:  
Cetuximab/Erbitux® 
Developer/Company:  
Cetuximab was developed by ImClone Systems Incorporated (Head office: 
New York, USA) and is manufactured by Bristol-Myer Squibb (Head office: 
Princeton, USA). Outside the USA and Canada, ImClone Systems Incorpo-
rated granted exclusive rights for development and commercialization of 
Cetuximab to Merck KGaA, Darmstadt, Germany [1]. 
Description:  
Cetuximab belongs to the pharmacotherapeutic group of antineoplastic 
agents and monoclonal antibodies (ATC code: L01XC06). 
It is a chimeric murine or human monoclonal IgG1 antibody designed to spe-
cifically direct against the epidermal growth factor receptor (EGFR) on the 
surface of tumour cells. By binding to the EGFR, tumour cells no longer re-
ceive messages needed for growth, progression and spread. Therefore, 
cetuximab inhibits the proliferation and induces apoptosis of human tu-
mour cells expressing EGFR [2].  
The recommended treatment regimen consists of an initial starting dose of 
400 mg/m² body surface area intravenous (IV) infusion over two hours on 
day 1, followed by a weekly 250 mg/m² IV infusion over one hour in combi-
nation with a platinum-based double-agent chemotherapy regimen until dis-
ease progression or unacceptable toxicity [3]. Both Phase III [1, 4] trials in-
cluded in this report examined the clinical effectiveness and safety of 
cetuximab using this treatment regimen. 
2 Indication 
Cetuximab in combination with double-agent platinum-based chemother-
apy (cisplatin and vinorelbine) is indicated for first-line treatment of ad-
vanced and recurrent non-small cell lung cancer (NSCLC) [5]. Patients eli-
gible for the cetuximab chemotherapy regimen are ≥ 18 years of age, have an 
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 to 
2 and suffer from EGFR-expressing non-small cell lung cancer. 
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3 Burden of Disease 
Lung cancer is one of the leading types of cancer and causes of cancer deaths 
worldwide [6]. Generally, one can differentiate between small-cell lung can-
cer (SCLC 15%) and non-small cell lung cancer (NSCLC 85%) [5, 7]. Its 
primary risk factors are first-hand and second-hand smoke [5]. 
Often, lung cancer is diagnosed in advanced stages of the disease, therefore 
prognosis is poor [6, 7]. In patients with advanced disease, performance 
status1 is used to estimate patient’s prognosis and to establish a treatment 
plan. Patients with advanced disease and good prognosis (ECOG PS 0 to 1) 
are treated with double-agent chemotherapy, whereas patients with poor 
prognosis (ECOG PS 2 to 4) receive single-agent chemotherapy or best-
supportive care [5, 7, 8]. 
Although early stage lung cancer can be managed curatively, a population 
wide screening to detect lung cancer at an early stage is not recommended. 
Currently, several trials are ongoing to find out whether screening benefits 
lung cancer patients or not [5]. 
Early-stage disease, good performance status (ECOG PS 0, 1 or 2), absence 
of significant weight loss (not more than 5%) and female gender are the 
most important prognostic factors regarding the prediction of survival of 
NSCLC patients. Age and histological subtypes do not play a major role in 
prognosis of tumour development [5] but in choice of treatment modalities 
and chemotherapeutic agents. Other prognostic and predictive factors for 
lung cancer response to cetuximab are biomarkers like epidermal growth 
factor receptor (EGFR) expression and mutational state, the occurrence of 
downstream signal transduction pathway modifications (K-Ras mutation) 
and others [5]. Unfortunately, the literature in the field of predictive factors 
is highly contradictory and controversial. For metastatic colorectal cancer, it 
was shown that the efficacy of cetuximab is clearly related to the absence of 
K-RAS mutations, but similar data for NSCLC are lacking or challenging to 
interpret (follow up of the FLEX trial, ASCO 2008, Pirker et al.)  
The most commonly used staging system of cancers in the trials included in 
this assessment is stage I-IV according to Union internationale contre le can-
cer (UICC) where stage I refers to a locally restricted, small primary tumour 
and stage IV represents metastatic, systemic disease. In its guidelines the 
National Comprehensive Cancer Network cites the international staging sys-
tem for lung cancer with reference to the American Joint Committee on 
Cancer (www.cancerstaging.net), where stages 0-IV are defined in detail re-
garding existence and size of primary tumour, existence and dimension of 
regional lymph nodes and distant metastasis [5]. 
Overall, 3,900 new cases of lung cancer were diagnosed in Austria in 2006, of 
which 31% were advanced, 13.3% were given death certificate only, and in 
19.5% of lung cancer patients cancer stage was not specified [9]. 
                                                             
1 Generally assessed by applicating the Eastern Cooperative Oncology Group 
(ECOG) or Karnofsky scale 7. Stinchcombe, T.E. and M.A. Socinski, Current 
treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc, 
2009. 6(2): p. 233-41.. 
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As no detailed data on incidence, survival rates and tumour development 
within the different NSCLC stages could be found for Austria, data from the 
United States of America (USA) will be shown in the following paragraphs. 
Overall, the incidence of NSCLC in the USA was 52 per 100,000 per year in 
2006. Among males, the incidence was 63 per 100,000 per year, whereas 
within females it was 45 per 100,000 per year in 2006 [10]. 
At the time of diagnosis of NSCLC, 17.5 (males 19.9 and females 15.3) of 
100,000 US-citizens are under 65 years of age and 315.2 (males 406.0 and 
females 252.3) of 100,000 US-citizens are aged ≥ 65 years [10]. On average, 
patients are 71 years old at the time of diagnosis of lung and bronchus can-
cer. 
In 2005 the 1-year survival rate for patients with cancer of the lung and 
bronchus of all stages was 44.4% [10]. The 5-year survival rate in NSCLC 
depends on both tumour stage and patient’s age at diagnosis and is 17.2% 
for all stages of NSCLC. Furthermore, the five-year survival rate is 54.2%, 
25.2%, 3.7% and 8.5% for localized, regional, distant and unstaged NSCLC, 
respectively. In addition, it is 25.7% in individuals aged under 45 years and 
decreases to 15.1% in patients > 65 years of age [10]. 
4 Current treatment 
Treatment of NSCLC is based on cancer stage (I-IV) at diagnosis and ECOG 
performance status and can encompass surgery, radiotherapy, chemother-
apy, targeted therapy and best supportive care [5, 6] as well as multi-modal 
approaches. Patients with early stage disease are treated with surgery, 
whereas individuals with locally advanced disease are either treated with ra-
diotherapy alone or in combination with chemotherapy, and neo-adjuvant 
approaches. Patients with advanced disease are treated either with chemo-
therapy alone [8] or targeted therapy alone, or with a combination of both. 
The targeted therapeutic agents geftinib, erlotinib and bevacizumab have 
been licensed for NSCLC in several countries.  
According to Stinchcombe and Socinski 2009, the current standard of treat-
ment as first-line therapy in patients with advanced NSCLC is a double-
agent chemotherapy regimen, consisting of one platinum-based agent (cis-
platin, carboplatin) in combination with a second agent (paclitaxel, gemcit-
abine, vinorelbine or docetaxel and pemetrexed in patients with non-
squamous histology) [5, 7]. 
Besides the targeted agents already licensed for NSCLC treatment (see 
above), multiple additional agents are in phase I, II or III developmental 
stages [11]. 
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5 Current regulatory status 
Cetuximab was approved for squamous cell carcinoma of the head and neck 
by the European Medicines Agency (EMEA) in March 2006 and by the 
United States Food and Drug Administration (FDA) in May 2006. Further-
more, it was approved for EGFR-expressing colorectal cancer by EMEA in 
March 2004 and by FDA in February 2004 [12, 13].  
 
Cancer of the colon or rectum: 
The use of cetuximab is indicated in EGFR-expressing colorectal cancer in 
combination with other anti-cancer medicines or as a single-agent when pre-
vious cancer therapy containing both irinotecan and oxaliplatin has failed. 
Its use is not recommended in patients whose tumour has K-RAS mutations 
[12, 13]. 
 
Head and neck cancer: 
For the treatment of locally or regionally advanced squamous cell carcinoma 
of the head and neck, cetuximab is approved in combination with radiation 
therapy. In recurrent or metastatic squamous cell carcinoma of the head and 
neck, cetuximab can be used in combination with platinum-based antican-
cer therapy like cisplatin and carboplatin [12, 13]. 
6 Evidence 
Based on a literature search in the databases PubMed, Embase and CRD 
and on a hand search, two Phase III trials and six Phase II trials evaluating 
the effect of cetuximab in patients with advanced lung cancer were found 
[14-19]. Four of these trials were single-arm trials [14, 15, 17, 18] with the 
purpose of finding the most promising modality of combining cetuximab 
with different standard of care chemotherapy regimens. None of these four 
studies assessed cetuximab in combination with cisplatin or vinorelbine and 
two of them evaluated cetuximab in combination with a taxane (paclitaxel or 
docetaxel) plus carboplatin, the same regimen as used in the BMS 099 trial. 
The remaining two phase II trials [16, 19] were two-arm trials assessing the 
activity and safety of cetuximab in combination with platinum-based dou-
ble-agent chemotherapy in comparison to platinum-based double-agent 
chemotherapy alone in patients with advanced NSCLC. 
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6.1 Efficacy and safety – Phase III studies 
 
Reference NCT00112294 (BMS 099), Abstract 
[20], not published [4] 
NCT00148798 (FLEX), published [1] 
Sponsor Merck KGaA, ImClone LLC Merck KGaA 
Country Multicenter – United States Multicenter – Europe, Asia, America 
Design Randomized, open-label, active control Randomized, open-label, active con-
trol 
Participants 676 patients (pts) (I 338 vs C 338); me-
dian age 65 years (34-87 years) 
1125 pts (I 557 vs C 568); median age 
I 59 years (18-78 years), C 60 years 
(20-83 years) 
Treatment I(ntervention): taxane, carboplatin and 
cetuximab  
C(ontrol): taxane, carboplatin alone 
(max 6 cycles, 1 cycle=3 weeks) 
Chemotherapy: taxane (either pacli-
taxel 225 mg/m2 dL infusion over 3h on 
d1, then every 3 weeks, or docetaxel 75 
mg/m2 dL infusion over 1h on d1, then 
every 3 weeks, and carboplatin (infu-
sion over 0.5h on d1, then every 3 
weeks);  
Cetuximab: IV infusion on d1; initial 
dose of 400 mg/m2, from d8 onwards 
250 mg/m2 weekly 
I(ntervention): cisplatin, vinorelbine 
and cetuximab 
C(ontrol): cisplating, vinorelbine 
alone (max 6 cycles, 1 cycle=3 
weeks) 
Chemotherapy (one cycle): cisplatin 
(80 mg/m2 intravenous (IV) infu-
sion on day (d) 1) and vinorelbine 25 
mg/m2 IV infusion on d1, 8 of every 
3-week cycle for up to 6 cycles);  
Cetuximab: IV infusion on d1; initial 
dose of 400 mg/m2 over 2h, from d8 
onwards 250 mg/m2 weekly 
In-/exclusion criteria Stage IIIb with malignant pleural effu-
sion or stage IV NSCLC, recurrent dis-
ease after surgery or radiation therapy, 
age ≥18 years, ECOG PS* 0-1 at study 
entry 
 
Inclusion criteria: chemotherapy-
naive stage IIIb or IV NSCLC, EGFR 
expression, age ≥18 years, ECOG PS 
0-2, adequate organ function, pres-
ence of at least one bi-dimensionally 
measurable tumour lesion; 
Exclusion criteria: brain metastases, 
previous treatment with EGFR-
targeted drugs or monoclonal anti-
bodies, major surgery within 4 
weeks or chest irradiation within 12 
weeks before study entry, active in-
fection, pregnancy, symptomatic pe-
ripheral neuropathy 
Follow-up cetuximab continued as single-agent 
until disease progression or unaccept-
able toxicity; 
Pts of both arms were assessed every 6 
weeks post dosing until disease pro-
gression or start of secondary chemo-
therapy 
cetuximab continued after end of 
chemotherapy until disease progres-
sion or unacceptable toxicity;  
median follow-up time 23.8 months 
(95% CI: I 22.1, 24.9 vs C 22.4, 24.8) 
Outcomes Primary: progression-free survival 
(PFS) 
Secondary: tumour response, overall 
survival, symptom response and symp-
tomatic progression, safety 
Primary: overall survival (OS) 
Secondary: progression-free sur-
vival, best overall response (OR), 
quality of life, safety 
Horizon Scanning in Oncology 
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Results Median PFS: I 4.4 months (95% CI: 
4.11, 5.06) vs C 4.24 months (95% CI: 
3.94, 4.63); HR=0.902 (95% CI: 0.761, 
1.069; p=0.2358) 
Response rate: Odds Ratio: 1.675 (95% 
CI: 1.152, 2.436) 
OS: not significantly different between 
I and C: HR= 0.931 (99.99% CI: 0.638, 
1.359; p=0.4639) 
Median survival: I 9.53 months vs C  
8.38 months 
Median OS: I 11.3 months (95% CI 
9.3-12.4) vs C 10.1 months (95% CI 
9.1-10.9), HR= 0.871 (95% CI 0.762-
0.996; p= 0.044); 1-year survival 
47% and 42%, respectively  
Median PFS: 4.8 months in both 
groups (I 95% CI 4.2-5.3, C 95% CI 
4.4-5.4); HR=0.943 (95% CI 0.825 – 
1.077); p= 0.39) 
 
Adverse events (AEs) Grade 3/4 AEs (I vs C): 
Acneform rash (10.8% vs 0%); infu-
sion reaction (5.5% vs 0.9%) 
AEs (any grade) that led to discon-
tinuation of study drugs (I vs C): 
cetuximab 30.5% vs 0%; (99 of 325 vs. 
0 of 320), taxane 24.6% vs 17.2% (80 
of 325 vs. 55 of 320), carboplatin 
24.0% vs 16.6% (78 of 325 vs 53 of 
320) 
Selected cardiac events: I 3.7% vs C 
1.6% 
Grade 3/4 AEs (I vs C): 
Acne like skin rash grade 3: 10% vs 
1% (p=0.0001); haematological ad-
verse effects: febrile neutropenia 
grade 3/4: I 16%/6% vs C 11%/4% 
(p=0.0086); leucopoenia grade 3/4: 
I 15%/10% vs C 14%/5% (p=0.02); 
sepsis grade 3/4: I 0%/2% vs C 
1%/1% (p=0.053);  treatment-
related deaths: 3% (15 of 548) vs 2% 
(10 of 562); cardiac events** grade 
3/4: I 2%/4% (31 pts of 548) vs. C 
3%/2% (28pts of 562pts), (p=0.69) 
Commentary Addition of cetuximab to taxane and 
carboplatin resulted in increased toxic-
ity, although safety profile was consis-
tent with previous clinical studies and 
treatment was tolerable and feasible. 
Certain patients benefit more from 
therapy with cetuximab. 
No significant differences were 
found in assessing quality of life – 
results might be affected by the low 
return rate of the questionnaires 
(70% at baseline, <15% at end of 
study). 
 
* ECOG PS: Eastern Cooperative Oncology Group performance status (details at: 
http://ecog.dfci.harvard.edu/general/perf_stat.html) 
** Cardiac events consisted of five medical concepts: arrest, arrhythmia (I: 12 vs. C: 
17), congestive heart failure (9 vs. 9), ischemia or infarction (8 vs. 4) and sud-
den death (2 vs. 0) 
Abbreviations: pts – patients, I – intervention group, C – control group, vs – versus, 
IV - intravenous, NSCLC – Non-small Cell Lung Cancer, EGFR – epidermal 
growth factor receptor, OS – overall survival, OR – overall response, PFS – 
progression free survival, AE – adverse events, CI – confidence interval, HR – 
Hazard Ratio, p – p-value. 
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6.2 Efficacy and safety - further studies 
Rosell et al. 2008 [19] conducted a phase II trial comparing cisplatin and vi-
norelbine alone and in combination with cetuximab in patients with EGFR-
expressing, advanced NSCLC. The main purpose of this trial was to assess 
the add-on activity of cetuximab to standard of care chemotherapy in ad-
vanced NSCLC. The dosing regimen and mode of administration of drugs as 
well as eligibility criteria for patients match with those from the FLEX-trial 
[1]. Main outcomes of this study were median progression-free survival (I: 
5.0 months (95% CI: 4.5, 5.8) months vs. C: 4.6 months (95% CI: 2.5, 6.0); 
HR 0.71 (95% CI: 0,4, 1.2)), progression-free survival rates at 12 months (I: 
15% (95% CI: 1%, 29%) vs. C: 0%), and best overall response rate (all partial 
responses) (I: 15 pts (35%; 95% CI: 21%, 51%) vs. C: 12 pts (28%; 95% CI: 
15%, 44%). Regarding the safety of treatment, non-haematological grade 3/4 
adverse events were similar in the two groups but differences between 
treatment arms were observed concerning the following grade 3/4 adverse 
events: asthenia (I: 19% vs. C: 2%), respiratory symptoms (I: 12% vs. C: 2%) 
and skin toxicities (I: 10% vs. C: none). 
Butts et al. 2007 [16] assessed the efficacy of cetuximab with gemcit-
abine/platinum chemotherapy (I: 65 patients), or gemcitabine/platinum 
chemotherapy alone (C: 66 patients) in first-line therapy for ad-
vanced/metastatic NSCLC in an open-label, non-comparative randomized 
phase II trial. None of the patients reached complete response – 18 out of 65 
patients in the cetuximab-arm (27.7%; 95% CI: 17.3%, 40.2%) and 12 out of 
66 patients (18.2%; 95% CI: 9.8%, 29.6%) in the control-arm achieved par-
tial response. The median progression free survival was 5.09 months (95% 
CI: 4.17, 5.98) and 4.21 months (95% CI: 3.81, 5.49), respectively. Median 
overall survival for the intervention group was 11.99 months (95% CI: 8.8, 
15.2) and 9.26 months for the control group (95% CI: 7.43, 11.79).  
Discontinuation of treatment was due to study drug toxicity (I: 12 pts 
(18.5%) vs. C: 7 pts (10.6%)) and disease progression/relapse (I: 32 pts 
(49.2%) vs. C: 17 (25.8%)). The most common grade 3/4 adverse events in 
the cetuximab-arm were acneiforme rash (I: 9 pts (14.1%) vs. C: 0 pts), 
thrombocytopenia (I: 37 pts (57.8%) vs. C: 29 pts (44.6%)) and anaemia (I: 
17 pts (26.6%) vs. C: 13 pts (20.0%)). 
7 Estimated costs  
One 100 ml vial Erbitux® (5mg/ml) solution is approximately € 980. For one 
patient an 18-week course is therefore expected to be around € 17,640 (as-
suming a body surface area of 1.7m² and therefore using 1 vial per week). 
The initial starting dose of cetuximab of 400 mg/m² is not included in this 
calculation and would be an additional € 1,960 (2 vials à € 980). These costs 
arise in addition to current chemotherapy regimes. 
As no long term data for the use of cetuximab in NSCLC patients are avail-
able, we based the calculation of treatment costs on the median duration of 
treatment presented in the FLEX-trial [1]. 
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8 Ongoing research 
Overall, six phase III trials evaluating cetuximab in NSCLC are registered 
at the freely accessible webpage www.clinicaltrials.gov, where international 
clinical trials are registered. 
Two of these six trials are already completed [1, 4], three are currently re-
cruiting patients and one is not yet open for participant recruitment. 
NCT00095199: will assess whether the addition of cetuximab to either do-
cetaxel or pemetrexed is effective in treating patients with recurrent or pro-
gressive NSCLC after failure of an initial platinum-based cancer therapy. 
Estimated study completion date is October 2009. 
NCT00946712: will compare how well carboplatin and paclitaxel work with 
or without bevacizumab and/or cetuximab in treating patients with stage IV 
or recurrent NSCLC. Estimated study completion date is June 2012. 
NCT00820755: is evaluating the activity and safety of cetuximab after plati-
num-based chemotherapy in combination with cetuximab as first-line 
treatment for individuals with advanced NSCLC. 
NCT00533949: will find out how well high-dose radiation therapy given in 
combination with cetuximab works compared to standard-dose radiation 
therapy and chemotherapy in treating patients with newly diagnosed stage 
III NSCLC that cannot be removed by surgery. 
9 Commentary - English 
Both phase III trials evaluating safety and efficacy of adding cetuximab to 
platinum-based double-agent chemotherapy showed higher toxicity rates 
and more serious adverse events in the cetuximab arm than in the control 
arm. The most common adverse events were acne like skin rash, cardiac 
events, febrile neutropenia, leucopenia, asthenia, respiratory symptoms, 
anaemia and treatment related deaths [1, 4, 16, 19, 20]. In mCRC the occur-
rence of skin toxicity is known to correlate with treatment responses. In this 
regard, studies investigating “dose escalation until toxicity occurs” are under 
way.    
Only one trial addressed quality of life of NSCLC patients treated with 
cetuximab and chemotherapy and could not show significant differences be-
tween the study arms [1], probably due to the fact that only few question-
naires assessing quality of life were returned. 
Minor increases in either PFS or median OS were found, if cetuximab was 
added to chemotherapy. On average, PFS is longer in patients receiving che-
motherapy and cetuximab (4.4 to 5.09 months) than in patients treated with 
chemotherapy alone (4.24 to 4.8 months). In terms of OS, trial results show a 
difference of 0 to 2.73 months between study groups (I: 8.3 to 11.99 months 
vs. C: 7.3 to 10.1 months). Accordingly, shortly before this assessments was 
published, a meta-analysis of four phase II/III trials [1, 16, 19, 20] was pre-
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sented at the ECCO 15 – 34th ESMO Multidisciplinary Congress2 that con-
cluded that cetuximab improves the efficacy of NSCLC therapy when added 
to a standard first-line chemotherapy (OS (HR 0.878; 95% CI: 0.795 to 0.969; 
p=0.01), PFS (HR 0.899; 95% CI: 0.814 to 0.993; P=0.036), and overall re-
sponse rate  (odds ratio 1.463; 95% CI: 1.201 to 1.783; p<0.001)) [21]. 
While overall and 1-year survival results of the FLEX trial favour the dou-
ble-agent chemotherapy in combination with cetuximab, BMS 099 could not 
show superiority of chemotherapy plus cetuximab compared to chemother-
apy alone. It is assumed that this is because patients were selected by their 
EGFR status in the FLEX-trial but not in BMS 099 [22], although EGFR 
positivity was defined quite liberal in the FLEX study as “demonstration of 
the existence of at least a single EGFR expressing tumor cell.” Thus, giving 
reason for hope that more stringent definitions will allow the characterisa-
tion of patient populations with a high probability of treatment responses. 
Patient selection plays an essential role in the treatment of advanced 
NSCLC with targeted therapies, such as tyrosine kinase inhibitors and 
monoclonal antibodies [18]. The selection of patients on the basis of bio-
markers is not standardized yet and it is unclear which patients will benefit 
the most from any given therapy. Therefore, before the widespread clinical 
use of biomarkers for patient selection and choice of treatment, the detection 
and use of biomarkers in prediction of patient survival needs to be urgently 
clarified in prospective clinical trials [1, 23, 24]. Nevertheless, despite the 
uncertainty surrounding the predictive potential of biomarkers with regards 
to NSCLC, the EMEA has narrowed down the indication of cetuximab for 
the treatment of mCRC: since 2008, it is only authorized for K-RAS wild-
type mCRC.  
Merck KGaA already applied for marketing authorisation of cetuximab in 
NSCLC at the EMEA which was refused by the EMEA in July 2009 due to 
major concerns whether the additional benefits could outweigh the side ef-
fects caused by cetuximab therapy [25]. 
Finally, the risks and benefits of adding cetuximab to standard of care che-
motherapy in patients with advanced or metastatic NSCLC have to be bal-
anced carefully. The application of cetuximab is, not only from the patient’s 
perspective – minor benefit and high risk of minor side effects – question-
able, but also from the societal perspective regarding the economic impact of 
the therapy. Treatment costs for cetuximab therapy are high in comparison 
to the benefit gained and arise in addition to chemotherapy. 
10 Commentary - German 
Die beiden eingeschlossenen Studien zu Cetuximab in Kombination mit ei-
ner Standardchemotherapie bei Patienten mit nicht-kleinzelligem Lungen-
karzinom (NSCLC) zeigen höhere Toxizitätsraten und einige schwerwie-
gendere Nebenwirkungen im Cetuximab-Arm verglichen mit dem Kontroll-
Arm. Die bedeutendsten Nebenwirkungen waren akneiformer Hautaus-
                                                             
2 ECCO – European Cancer Organisation; ESMO – European Society for Medical 
Oncology 
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schlag, kardiologische Ereignisse, febrile Neutropenie, Leukopenie, Asthe-
nie, Atemwegsbeschwerden, Anämie und behandlungsbedingte Todesfälle 
[1, 4, 16, 19].  
Nur eine Studie erhob die Lebensqualität von NSCLC-PatientInnen und 
konnte im Vergleich der Studienarme – Chemotherapie ± Cetuximab – kei-
ne signifikanten oder klinisch relevanten Unterschiede aufzeigen [1]. 
Im Hinblick auf progressionsfreies Überleben (PFS) und Gesamtüberleben 
(OS) konnten nur minimale Verbesserungen bei der zusätzlichen Verabrei-
chung von Cetuximab zur Chemotherapie beobachtet werden. Durch-
schnittlich beträgt das progressionsfreie Überleben des nicht-kleinzelligen 
Lungenkarzinoms mit der Kombination Standardchemotherapie plus Cetu-
ximab 4.4 bis 5.09 Monate) und mit Chemotherapie alleine 4.24 bis 4.8 Mo-
nate. Das OS verlängert sich im Durchschnitt um 0 bis 2.73 Monate bei zu-
sätzlicher Verabreichung von Cetuximab zu Chemotherapie (I: 8.3 bis 11.99 
Monate; C: 7.3 bis 10.1 Monate). Eine Metaanalyse [21], die kurz vor Er-
scheinen dieses Berichts am 15. Kongress der European Cancer Organisati-
on (ECCO 15) präsentiert wurde, schlussfolgerte, dass Cetuximab in Kom-
bination mit Standard first-line Chemotherapie die Wirksamkeit der 
NSCLC-Therapie verbessert ((OS (HR 0.878; 95% CI: 0.795, 0.969, p=0.01), 
PFS (HR 0.899; 95% CI: 0.814, 0.993; P=0.036), and ORR (odds ratio 1.463; 
95% CI: 1.201, 1.783; p<0.001)). 
Während in der FLEX-Studie die Kombination Chemotherapie plus Cetu-
ximab zu einer höheren Gesamt- und 1-Jahres-Überlebensrate als Chemo-
therapie alleine führte, konnte dieses Ergebnis von der BMS 099-Studie 
nicht bestätigt werden. Man nimmt an, dass dieser Unterschied in der Pati-
entInnenselektion zu finden sei, weil bei der FLEX-Studie die PatientInnen 
mittels EGFR-Status ausgewählt wurden und innerhalb BMS 099 nicht [22]. 
Das positivere Ergebnis der FLEX Studie konnte erreicht werden, obwohl 
die Definition eines positiven EGFR Status sehr weitgefasst war (Nachweis 
einer einzigen EGFR positiven Tumorzelle). Dies lässt hoffen, dass mittels 
Einsatz stringenterer Kriterien (EGFR Expression, Mutation, und K-RAS 
Status) die Identifikation von PatientInnen-Subgruppen mit hoher Wahr-
scheinlichkeit eines Therapieansprechens möglich wird. 
PatientInnenselektion spielt eine wesentliche Rolle in der Behandlung von 
PatientInnen mit NSCLC mit gezielten Therapien wie Tyrosinkinase-
Inhibitoren und monoklonalen Antikörpern [18]. Da die PatientInnenselek-
tion mittels Biomarkern noch nicht standardisiert und im Einzelfall unklar 
ist, welcher Nutzen für PatientInnen daraus entsteht, sollten Biomarker vor 
der breiten klinischen Anwendung für PatientInnenselektion, Therapiewahl 
und Vorhersage des Krankheitsverlaufs in prospektiven klinischen Studien 
dringend sorgfältig untersucht werden [1, 23, 24]. Im Falle von mCRC hat 
der K-RAS Mutationsstatus, allerdings basierend auf Ergebnissen retrospek-
tiver Studien, Eingang in die EMEA Zulassung von Cetuximab gefunden.  
Merck KGaA hat einen Antrag auf Zulassung von Cetuximab bei PatientIn-
nen mit NSCLC bei der EMEA eingereicht, welcher im Juli 2009 aufgrund 
erheblicher Bedenken zu Nutzen und Risiken der Therapie abgelehnt wurde 
[25]. 
Schlussendlich müssen Risiken und Nutzen von Cetuximab in Kombination 
mit Standardtherapie sorgfältig abgewogen werden. Der Einsatz von Cetu-
ximab ist nicht nur aus PatientInnenperspektive – geringer Nutzen und 
mögliche Nebenwirkungen – fraglich, sondern auch aus gesellschaftlicher 
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Perspektive im Hinblick auf die ökonomischen Auswirkungen der Therapie. 
Die Behandlungskosten von Cetuximab sind im Vergleich zum Nutzen hoch 
und entstehen zusätzlich zur Standard(chemo)therapie.  
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